2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163806
    NT376 2820208-97-5 98%
    NT376 is a high potency and selectivity inhibitor of class-IIa Histone deacetylases (HDAC) with an IC50 value of 32 nM, similar to NT160 (HY-149285) (IC50= 46 nM) in HT-29 cells. NT376 is proming for research of various cancers and in the diseases of the central nervous system (CNS) such as Alzheimer’s and Huntington’s diseases.
    NT376
  • HY-16381B
    Pasireotide (diaspartate) 1421446-02-7 98%
    Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity.
    Pasireotide (diaspartate)
  • HY-163825
    RNB-61 98%
    RNB-61 is an oral active agonist of cannabinoid CB2 receptor (CB2R), with the Ki ranging from 0.13 nM to 1.81 nM. RNB-61 has nephroprotective and/or antifibrotic effects. RNB-61 has negligible penetration into the brain.
    RNB-61
  • HY-163830
    Pegasus 98%
    Pegasus (DAD9) is a potent dopamine receptor agonist. Pegasus shows antioxidant and anti-inflammatory properties. Pegasus inhibits α-Syn amyloid aggregation. Pegasus has the potential for the research of Parkinson’s disease.
    Pegasus
  • HY-163831
    AZ12559322 947184-66-9 98%
    AZ12559322 is a positive allosteric modulator of mGluR2, with the Ki value of 1.31 nM. AZ12559322 can be used in neurological research.
    AZ12559322
  • HY-163840
    GFRα2/3-IN-1 98%
    GFRα2/3-IN-1 (Compound 16) is a selective GFRα2/3 inhibitor with IC50 values of 0.1 and 0.2 μM for GFRα2 and GFRα3, respectively. GFRα2 is a glial cell line-derived neurotrophic factor (GDNF) receptor related to GFRα1, GFRα2/3-IN-1 can be used for pain and itch research.
    GFRα2/3-IN-1
  • HY-163861
    Tl45b 98%
    Tl45b is an AChE inhibitor, with an IC50 of 0.71 μM. Tl45b can be used for the research of Alzheimer’s disease.
    Tl45b
  • HY-163879
    hMAO-B-IN-9 98%
    hMAO-B-IN-9 (Compound 25c) is a non-competitive inhibitor for monoamine oxidase B (MAO-B) with an IC50 of 1.58 µM (hMAO-B). hMAO-B-IN-9 forms complex with iron ions as a chelator, and inhibits Erastin (HY-15763)-induced ferroptosis. hMAO-B-IN-9 exhibits antioxidant activity by downregulating the level of reactive oxygen species (ROS). hMAO-B-IN-9 improves cognitive function in mice, without significant toxicity (30 mg/kg). hMAO-B-IN-9 is blood-brain barrier permeable, according to the in silico prediction.
    hMAO-B-IN-9
  • HY-163883
    BChE-IN-34 2215768-12-8 98%
    BChE-IN-34 is a potent and selective butyrylcholinesterase (BChE) inhibitor with an IIC50 of 25 nM. BChE-IN-34 shows excellent selectivity against BChE over acetylcholinesterase. BChE-IN-34 has neuroprotective and antioxidant effects.
    BChE-IN-34
  • HY-163885
    SSZ 1262287-23-9 98.13%
    SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice.
    SSZ
  • HY-163895
    δ opioid receptor antagonist 1 98%
    δ opioid receptor antagonist 1 (compound 6-Cy3) is a fluorescent antagonist probe with high selectivity for δ opioid receptor (DOR) (Ki=1.7 nM). δ opioid receptor antagonist 1 can be used to study the mechanism of pain perception.
    δ opioid receptor antagonist 1
  • HY-163909
    AChE-IN-72 98%
    AChE-IN-72 (Compound 13a) is an inhibitor for acetylcholinesterase (AChE) with an IC50 of 0.59 μM. AChE-IN-72 inhibits BChE with an IC50 of 5.02 μM. AChE-IN-72 exhibits radical scavenging with IC50 of 5.88 μM. AChE-IN-72 exhibits iron-chelating property, inhibits Aβ1−42 aggregation, and inhibits NLRP3 inflammasome activation. AChE-IN-72 ameliorates memory impairment in Betaine (HY-B0710)-induced AD mouse model. AChE-IN-72 is blood-brain barrier (BBB) penetrable.
    AChE-IN-72
  • HY-163916
    SalA-VS-07 2445895-33-8 98%
    SalA-VS-07 is a G protein-biased partial agonist for the Kappa-opioid receptor (KOR). SalA-VS-07 can be used for research of pain and other disorders.
    SalA-VS-07
  • HY-163917
    SalA-VS-08 2439152-14-2 98%
    SalA-VS-08 is a full agonist of kappa-opioid receptor (KOR) with selectivity and G-protein bias. SalA-VS-08 can be used in the research of analgesia.
    SalA-VS-08
  • HY-163974
    MRS7292 2092913-97-6 98%
    MRS7292 is a non-competitive inhibitor of human dopamine transporter (hDAT). MRS7292 inhibits dopamine transport.
    MRS7292
  • HY-163978
    YGZ-331 1350113-04-0 98%
    YGZ-331 is a sedative with a calming effect. YGZ-331 is a derivative of the adenosine nucleoside NGBA, which can increase GABA levels. YGZ-331 exerts a sedative-hypnotic effect by activating A1R and A2aR, and inhibiting CaMKII phosphorylation (pCaMKII) levels. YGZ-331 can reduce the spontaneous motor activity of mice.
    YGZ-331
  • HY-164083
    GR65630 113140-33-3 98%
    GR65630 is a potent and selective 5-hydroxytryptamine (5-HT) type 3 receptor antagonist. GR65630 can be used to study the expression patterns of 5-HT3 receptors in different brain regions and their possible functions in the central nervous system. GR65630 and its radiolabeled form [3H]GR65630 can be used to study the distribution, density and affinity of the receptors.
    GR65630
  • HY-164111
    JNK-IN-17 1128096-58-1
    JNK-IN-17 (Compound 9J) is a selective and potent JNK inhibitor with IC50 values of 0.039, 0.079 μM for JNK1 and JNK3. JNK-IN-17 can inhibit c-Jun phosphorylation with an IC50 of 0.082 μM in Streptozotocin (HY-13753)-infuced INS-1 pancreatic islet β cells. JNK-IN-17 shows inhibition rate ≤ 33% on the four main P450 subtypes (2C9, 2D6, 3A4, 1A2) in human liver microsomes, indicating a relatively low risk of drug interactions. JNK-IN-17 can be used for researches of neurological and metabolic disease, such as Parkinson's disease.
    JNK-IN-17
  • HY-164290
    Rhodady C10 1367579-04-1 98%
    Rhodady C10 (Compound C10) is a dynamin I GTPase inhibitor. Rhodady C10 blocks receptor-mediated endocytosis (IC50: 7 μM). Dynamin is involved in clathrin-independent endocytosis, phagocytosis, and caveolae internalization.
    Rhodady C10
  • HY-164298
    MRGPRX2 modulator-3 2765728-26-3
    MRGPRX2 modulator-3 (Compound 4-400) is a quinoline derivative and a MRGPRX2 modulator. MRGPRX2 modulator-3 can be used in the research of MRGPRX2-related diseases, such as allergies, pruritus, pain, inflammation and autoimmune diseases, etc.
    MRGPRX2 modulator-3
Cat. No. Product Name / Synonyms Application Reactivity